
APYX Stock Forecast & Price Target
APYX Analyst Ratings
Bulls say
Apyx Medical is a company with a strong position in the cosmetic surgery market, driven by the success of its Renuvion platform. This platform utilizes a unique helium plasma technology to tighten loose or lax skin. The recently launched Ayon all-in-one body contouring system has the potential to drive further growth by providing a comprehensive solution for surgeons. Apyx's focus on the surgical skin tightening market, favorable market trends, and expanding recurring revenue mix position the company for sustainable cash flow generation and potential valuation multiple expansion.
Bears say
Apyx Medical is expected to experience a decline in revenue due to decreased demand for its Renuvion technology following the FDA's safety communication in 2022, but this could potentially be offset by the launch of its new Ayon product and expanded FDA clearance for its J-Plasma system in 2026. However, risks such as potential liability from product liability matters, inconsistent commercial execution, and regulatory delays could impact the company's financial performance. Additionally, with a history of net losses and significant outstanding debt, the company's financial stability could be a concern.
This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
APYX Analyst Forecast & Price Prediction
Start investing in APYX
Order type
Buy in
Order amount
Est. shares
0 shares